Ring Therapeutics is a biotechnology start-up based in Cambridge, Massachusetts, on a mission to revolutionize gene therapy. The company has recently raised $86.5 million in a Series C funding round, with investors including The Invus Group, Flagship Pioneering, Partners Capital, CJ Investment Inc., and Kyowa Kirin, Inc.- U.S.

They develop a new approach to gene therapy that addresses these challenges. The company's technology uses a small circular DNA molecule called a "ring" to deliver genes to cells more efficiently. The ring can also carry more complex genes, expanding the range of genetic disorders targeted by gene therapy.

The potential of Ring Therapeutics' technology has attracted significant interest from investors and partners in the biotechnology industry. In addition to the recent funding round, the company has partnered with leading gene therapy companies, such as Novartis and Beam Therapeutics, to advance its research and development efforts.

Ring Therapeutics' innovative approach to gene therapy can potentially transform the lives of millions of people with genetic disorders. The company's focus on safety, efficacy, and affordability could make gene therapy more accessible to patients.

Check the latest funding round: https://founderlodge.com/round/Ring-Therapeutics-raises-86500000-Series-C-2023-03-10-Tuyen-Ong-MTA2MTA.